Table 8.

Additional points suggested by authors for quality of clinical trials and its evaluation.

Ethnopharmacological relevance of the plant	Proper preliminary literature or data (in vitro animal models, cell culture studies, etc) needed to establish the role in diabetes
Identification and taxonomy of planta. information regarding taxonomy	Identification of the correct plant and its part via authentic sources including herbarium, taxonomist, botanist and botanical gardens
b. information about plant part to use	Phytochemical screening for different plant parts with in vivo and in vitro models of pharmacological activities
c. quality variation and standardization	Quality variation for the same plant in terms of different geographical origins need to be standardized through green, short and reproducible analytical and pharmacological tools
Pharmacovigilance data of plant	Safety and efficacy data for Phase-0 with an extensive preclinical model for toxicity studies needed in order to rule out the side and adverse effects at a proper dose
Inclusion of co-markers treatment	Various non-conventional markers of stress, inflammation, glycation end products, etc, needs to be evaluated alongside the conventional markers